402 related articles for article (PubMed ID: 10516779)
1. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
Hohol MJ; Orav EJ; Weiner HL
Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
[TBL] [Abstract][Full Text] [Related]
2. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
4. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
5. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
6. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
7. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
Rabadi MH; Vincent AS
Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
[TBL] [Abstract][Full Text] [Related]
9. Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
Hobart J; Freeman J; Thompson A
Brain; 2000 May; 123 ( Pt 5)():1027-40. PubMed ID: 10775547
[TBL] [Abstract][Full Text] [Related]
10. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
11. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
[No Abstract] [Full Text] [Related]
12. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: clinical characteristics and disability progression in Moroccan children.
Ait Ben Haddou E; Alhyan M; Aasfara J; Regragui W; Ibrahimi A; Razine R; Abouqal R; Benomar A; Yahyaoui M
J Neurol Sci; 2014 Nov; 346(1-2):128-32. PubMed ID: 25216553
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
Thouvenot E; Orsini M; Daures JP; Camu W
Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
[TBL] [Abstract][Full Text] [Related]
15. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
Achiron A
J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.
Gold SM; Raji A; Huitinga I; Wiedemann K; Schulz KH; Heesen C
J Neuroimmunol; 2005 Aug; 165(1-2):186-91. PubMed ID: 15935481
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
Achiron A; Barak Y; Rotstein Z
Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
[TBL] [Abstract][Full Text] [Related]
18. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
[TBL] [Abstract][Full Text] [Related]
19. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
20. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]